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A Brief History of 180-Day Exclusivity Under the
Hatch-Waxman Amendments to the Federal Food,
Drug, and Cosmetic Act
ERIKA KING LrzAN*
I. INTRODUCTION
This article summarizes the history of the 180-day exclusivity provision in the Hatch-
Waxman Amendments to the Federal Food, Drug, and Cosmetic Act (FDCA).' Part II
presents the statutory language, as amended in the Medicare Prescription Drug, Improve-
ment, and Modernization Act of 2003 (MMA),2 and summarizes the law that applies to
new abbreviated new drug applications (ANDAs) (those filed after December 8, 2003,
provided there was no paragraph IV certification to the listed drug prior to December 8), as
well as the law that applies to all other ("old") ANDAs. Part III describes the legislative
history of the original 1984 provision and traces its judicial and administrative history
through the present. Part IV describes the history of the 2003 amendments and describes
the key changes made in 2003. While Congress addressed in 2003 a number of the interpre-
tive issues that had arisen since 1984, the new law is intricate and undoubtedly will give
rise to new interpretive questions in the months and years ahead.
II. OVERVIEW OF THE LAW
Section 505(b)(1) of the FDCA requires a new drug applicant to include in its new
drug application (NDA)
the patent number and the expiration date of any patent which claims the drug
for which the applicant submitted the application or which claims a method of
using such drug and with respect to which a claim of patent infringement could
reasonably be asserted if a person not licensed by the owner engaged in the
manufacture, use, or sale of the drug.'
The Food and Drug Administration (FDA) publishes these patent numbers and their
expiration dates in an Addendum to the Orange Book.4 FDA explains in the preface to
the Orange Book that "[p]atent information on unapproved applications or on patents
beyond the scope of the Act (i.e., process or manufacturing patents) will not be pub-
lished." Section 505(j)(2)(A) of the FDCA requires a generic applicant to include in its
ANDA, with respect to every "patent which claims the listed drug [on which the ANDA
*Ms. Lietzan is Assistant General Counsel, Pharmaceutical Research and Manufacturers of
America (PhRMA) in Washington, D.C. The opinions expressed herein are her own.
Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98
Stat. 1585 (1984). The 1984 amendments are commonly referred to by the last names of their
original Congressional co-sponsors, Senate Judiciary Committee Senator Orrin Hatch (R-UT) and
House Energy & Commerce Committee Representative Henry Waxman (D-CA).
2 Pub. L. No. 108-173, 117 Stat. 2066 (Dec. 8, 2003).
3 21 U.S.C. § 352(b)(1).
4 FOOD AND DRUG ADMIN., CENTER FOR DRUG EVALUATION AND RESEARCH, APPROVED DRUG PRODUCTS WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS ("Orange Book") (24th ed. Feb. 2004), available at http://
www.fda.gov/cder/ob/docs/preface/ecpreface.htm#Content and Exclusion (last accessed May 10, 2004).
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is based] or which claims a use for such listed drug for which the applicant is seeking
approval under [subsection 5050)] and for which information is required to be filed
under [subsection 505(b) or (c)]" a certification that one of the following is true: 1) the
patent information has not been filed by the NDA holder, 2) the patent has expired, 3) the
date on which the patent will expire, or 4) the patent is invalid or will not be infringed by
the manufacture, use, or sale of the new drug for which the ANDA is submitted.5
Sections 505(j)(5)(B)(iv) and 505(j)(5)(D) of the FDCA govern the 180-day exclusivity
available to the first generic applicant to file an ANDA challenging a patent held by the
innovator. Congress enacted these provisions in 1984 and amended them substantially
in 2003. Both the original and current language of these provisions are reproduced in the
Appendix to this article. With one exception, the new rules apply only prospectively.6
The core concept of 180-day exclusivity is that the first generic applicant to challenge
an innovator's patent is entitled to six months of exclusivity against subsequent generic
copies of the same innovator drug. This, it was thought, would encourage generic
applicants. 7 The concept was simple enough and the statutory language, described
infra, was correspondingly brief. No one at the time anticipated the deluge of interpre-
tive disputes and litigation that followed. No doubt, this in part explains the paucity of
legislative history on the provision. FDA made a valiant effort to adopt reasonable
implementing policies, but the agency was hampered by the lack of guidance in the
legislative history and by inflexible statutory language. In an earlier era, the courts might
have been more forgiving of FDA's exercise of its discretion in this situation, but the
1990s were a time of searching review of agency decisionmaking, 8 and, as discussed
infra, the agency lost a number of cases involving its application of 180-day exclusivity.
A. The Current Legislative Language Governing 180-Day Exclusivity
As amended in 2003, section 505(j)(5)(B)(iv) provides that
[i]f the [abbreviated new drug] application contains a certification described in
paragraph (2)(A)(vii)(IV) [otherwise known as a "paragraph IV certification"]
and is a drug for which a first applicant has submitted an application contain-
ing such a certification, the application shall be made effective on the date that
is 180 days after the date of the first commercial marketing of the drug (includ-
ing the commercial marketing of the listed drug) by any first applicant.9
Put another way, the first generic applicant to file an ANDA containing a paragraph IV
certification is awarded 180 days of marketing exclusivity, during which FDA may not
approve a subsequent ANDA with a paragraph IV certification for the same drug prod-
5 21 U.S.C. § 355j)(2)(A)(vii).
6 The new rules apply only to ANDAs filed after December 8, 2003, and only if there was no
paragraph IV certification for the listed drug prior to December 8. See Pub. L. No. 108-173 § 1102(b).
The exception relates to the "court decision" trigger for exclusivity, and it is explained infra at text
accompanying n.29.
I Apart from the so-called "paper NDA" process, FDA did not have a streamlined process for
approval of generic copies of brand-name drug products whose patents had expired. According to the
Federal Trade Commission (FTC), "[b]y 1984, the FDA estimated that there were approximately
150 brand-name drugs whose patents had expired for which there was no generic equivalent." GENERIC
DRUG ENTRY PRIOR TO PATENT EXPIRAnON: AN FTC STUDY (July 2002) (citing H.R. REP. No. 98-857, Part 1,
at 17 (1984)).
' See Erika King & Elizabeth Walsh, FDA in Court: Statistics on the Agency's Record in Recent
Years, FDLI UPDATE, July/Aug. 2002, at 34.
9 21 U.S.C. § 355(j)(5)(B)(iv).
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uct. The exclusivity period is calculated from the date of the first commercial marketing
of the drug product (including the listed drug product) by the first applicant.
Under section 505(j)(5)(D), the 180-day exclusivity period is forfeited if the first appli-
cant fails to market the drug by the later of: 1) 75 days after the date on which approval
of its application is effective, or 30 months after its application was submitted, which-
ever is earlier, or 2) 75 days after the date on which, as to each patent that is the subject
of a paragraph IV certification by the first applicant (qualifying it for exclusivity), a court
has found the patent invalid or not infringed, a court signs a settlement order or consent
decree finding the patent invalid or not infringed, or the patent information is withdrawn
by the holder of the approved NDA.
The 180-day exclusivity period also is forfeited if any of the following occurs: 1) the
first applicant withdraws its application or the Secretary considers it to have been
withdrawn because it did not meet the requirements for approval; 2) the first applicant
amends or withdraws all of the paragraph IV certifications that qualified it for exclusiv-
ity; 3) the first applicant fails to obtain tentative approval of its application within 30
months after it was filed (unless the failure is caused by a change in, or review of, the
requirements for approval of the application imposed after it was filed); 4) the first
applicant enters into an agreement with another ANDA applicant, the NDA holder, or a
patent holder, and the Federal Trade Commission (FTC) or a court has found that the
agreement violates the antitrust laws; or 5) all of the patents as to which the first
applicant filed a paragraph IV certification qualifying it for exclusivity have expired. If all
first applicants forfeit the 180-day exclusivity, any subsequent ANDA approval may be
made effective immediately-that is, exclusivity does not "roll over" to a subsequent
ANDA applicant.
B. The Prior Law Governing 180-Day Exclusivity
Between 1984 and 2003, section 505(j)(5)(B)(iv) of the FDCA provided that
If the [abbreviated new drug] application contains a certification described in
subclause (IV) of paragraph (2)(A)(vii) [otherwise known as a "paragraph IV
certification"] and is for a drug for which a previous application has been
submitted under this subsection continuing [sic "containing"] such a certifi-
cation, the application shall be made effective not earlier than one hundred and
eighty days after-(I) the date the Secretary receives notice from the applicant
under the previous application of the first commercial marketing of the drug
under the previous application, or (II) the date of a decision of a court in an
action described in clause (iii) holding the patent which is the subject of the
certification to be invalid or not infringed, whichever is earlier.10
Put another way, the first generic applicant to file an ANDA containing a paragraph IV
certification was to be awarded 180 days of marketing exclusivity, during which FDA
could not approve a subsequent ANDA with a paragraph IV certification for the same
drug product. The exclusivity period was calculated from either the date of the first
commercial marketing of the generic drug product or the date of a court decision declar-
ing the patent invalid or not infringed, whichever was sooner.
10 21 U.S.C. § 355(j)(5)(B)(iv) (1984) (amended 2003).
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C. The Rules Governing ANDAs Filed After December 8, 2003, If
There Was No Paragraph IV Certification for the Listed Drug Prior
to December 8 ("New" ANDAs)
The following are key interpretive questions about 180-day exclusivity and, after
each, an explanation of the current law and the source for that law (whether statute,
regulations, guidance, court decisions, legislative history, or some other document).
* Who is entitled to 180-day exclusivity? Exclusivity is awarded to the "first" appli-
cant to file a "substantially complete" ANDA with a paragraph IV certification. A
"substantially complete" ANDA is one that "on its face is sufficiently complete to
permit a substantive review" and that contains all of the information required by
section 505(j)(2)(A)." This was intended to continue prior FDA practice.'2
" If several applicants file ANDAs on the same day, which is entitled to 180-day
exclusivity? If multiple applicants file substantially complete ANDAs with paragraph
IV certifications on the same day as the first to do so, those applicants all are entitled
to exclusivity. 3 This result also is required by the new statutory language, which
precludes approval for 180 days after first commercial marketing by "any" first appli-
cant, and which precludes rollover if "all first applicants" forfeit their exclusivity. 4
" Must the ANDA applicantfile its paragraph IV certification and send notice to the
innovator on the same day? Where notice is provided after the certification is re-
ceived, agency policy under the statutory language in effect from 1984 to 2003 con-
structively moved the certification's submission date-which governs eligibility for
exclusivity- to the day on which the applicant mailed the notice. This was sustained
as a reasonable exercise of agency discretion. 5 Congress did not address this issue
in 2003, and it is reasonable to assume FDA's policy has not changed.
" Does 180-day exclusivity "roll over" to a second ANDA applicant in the event
that the first does not perfect its rights? No. In FDA's August 1999 draft regula-
tions, which were never finalized, the agency confirmed that exclusivity would not
roll to a second applicant, even if the first applicant withdrew its ANDA.'6 The new
legislation requires this result as well: if all first applicants forfeit exclusivity, "no
applicant shall be eligible."' 7
" Can there be separate exclusivity periods for different ANDA applicants who filed
paragraph IV certifications as to different listed patents for the same innovator
drug product, and for different applicants for different dosages of the same inno-
vator drug product? No. The new legislation abolished the patent-by-patent ap-
proach in favor of a product-by-product approach. If all first applicants forfeit
exclusivity, approval of "any" application containing "a" paragraph IV certification
may be made effective. 8
21 U.S.C. § 355(j)(5)(B)(iv)(ll)(cc) (added in 2003).
2 See 21 C.F.R. § 314.101(b)(1).
13 FDA, Guidance for Industry, 180-Day Exclusivity When Multiple ANDAs Are Submitted On the
Same Day (July 2003); 21 C.FR § 314.107(c)(2); 64 Fed. Reg. 42,873 (Aug. 6, 1999) (proposed regula-
tions).
" See 149 CONG. REc. S15584 (daily ed. Nov. 25, 2003) (statement of Sen. Kennedy) ("and the
exclusivity is available to more than one generic applicant, if they all challenge patents on the same day").
"5 Purepac Pharm. Co. v. Thompson, 2004 WL 76594 (D.C. Cir. Jan. 20, 2004), aff'g TorPharm
Inc. v. Thompson, 260 F. Supp. 2d 69 (D.D.C. 2003).
16 64 Fed. Reg. 42,873 (Aug. 6, 1999) (proposed regulations).
17 21 U.S.C. § 355(j)(5)(D)(iii).
1 Id. See also 149 CONG. REc. S15884 (daily ed. Nov. 25, 2003) (statement of Sen. Kennedy) ("The
Hatch-Waxman provisions in this bill also make the exclusivity available only with respect to the patent
or patents challenged on the first day generic applicants challenge brand drug patents, which makes the
exclusivity a product-by-product exclusivity rather than a patent-by-patent exclusivity.")
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" How do 180-day exclusivity and pediatric exclusivity interact? Under legislation
enacted in 2002, if a pioneer applicant earns six months of pediatric exclusivity, the
first generic applicant's ANDA is approved effective the first day after conclusion
of that exclusivity, and the 180 days begin at that point. The terms are consecu-
tive. 19 Congress did not address this issue again in 2003 so, presumably, the 2002
rule continues to apply.
" Are 180-day exclusivity rights waivable and/or transferable? Under agency policy
prior to 2003, the first generic may waive its 180-day exclusivity rights in favor of
another generic applicant (or in favor of no generic), for consideration.20 In some
instances, the consideration has been a royalty stream that would continue even
after exclusivity expired. Congress did not address this issue in 2003, and, presum-
ably, this continues to be agency policy.
" Will marketing by the first generic of the pioneer's product under a private ge-
neric label satisfy the commercial marketing trigger? Yes.21 Congress confirmed
this in 2003 with the addition of the words "including the commercial marketing of
the listed drug" in the sentence describing the trigger.
22
D. The Rules Governing All Other ("Old") ANDAs
The rules are different for an ANDA filed before December 8, 2003, as well as an
ANDA filed afterwards if a paragraph IV certification for the listed drug was filed before
December 8.
* Who is entitled to 180-day exclusivity? Exclusivity is awarded to the "first" appli-
cant to file a "substantially complete" ANDA with a paragraph IV certification. The
statute did not define "substantially complete," but FDA has "received" an ANDA
only if it is sufficiently complete to permit a substantive review.23 Among other
things, the ANDA needs to contain "the results of any required bioequivalence
studies or, if applicable, a request for a waiver of such studies."'24
* If several applicants file ANDAs on the same day, which is entitled to 180-day
exclusivity? If multiple applicants file substantially complete ANDAs with para-
graph IV certifications on the same day as the first to do so, those applicants all are
entitled to exclusivity.
25
* Must the ANDA applicant file its paragraph IV certification and send notice to
the innovator on the same day? Where notice is provided after the certification is
received, agency policy constructively moves the certification's submission date,
which governs eligibility for exclusivity, to the day on which the applicant mailed
the notice. This has been sustained as a reasonable exercise of agency discretion. 6
9 21 U.S.C. § 355A(k) (added by the Best Pharmaceuticals for Children Act, Pub. L. No. 107-
109, 115 Stat. 1408 (2002)).
21 See, e.g., 64 Fed. Reg. 42,873, 42,881 (Aug. 6, 1999) (proposed regulations); Boehringer
Ingelheim Corp. v. Shalala, 993 F. Supp. 1 (D.D.C. 1997).
21 See Mylan Pharm., Inc. v. Thompson, 207 F. Supp. 2d 476 (N.D. W. Va. 2001).
22 21 U.S.C. § 355(j)(5)(B)(iv)(I).
23 See 21 C.F.R. § 314.101(b)(1).
24 21 C.F.R. § 314.107(c)(2); 64 Fed. Reg. 42,873 (Aug. 6, 1999) (proposed regulations).
I FDA, Guidance for Industry, 180-Day Exclusivity When Multiple ANDAs Are Submitted On
the Same Day (July 2003); 21 C.ER § 314.107(c)(2); 64 Fed. Reg. 42,873 (Aug. 6, 1999) (proposed
regulations).
26 Purepac Pharm. Co. v. Thompson, 2004 WL 76594 (D.C. Cir. Jan. 20, 2004), aff'g TorPharm,
Inc. v. Thompson, 260 F. Supp. 2d 69 (D.D.C. 2003).
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" Does 180-day exclusivity "roll over" to a second ANDA applicant in the event
that the first does not perfect its rights? No. In FDA's August 1999 draft regula-
tions, which were never finalized, the agency confirmed that exclusivity would not
roll to a second applicant, even if the first applicant withdrew its ANDA. 7
" Must the generic applicant have itself prevailed in a patent infringement suit in
order to obtain the benefits of 180-day exclusivity? No. There is no "successful
defense" requirement. Another generic could prevail instead, or the case could be
dismissed.2"
" What level court decision will trigger the 180-day exclusivity? This is the sole
topic on which the 2003 legislation is retroactive. For ANDAs (i.e., those as to
which the new rules do not apply), exclusivity begins when a decision is rendered
by "the court from which no appeal (other than a petition of the Supreme Court for
a writ of certiorari) has been or can be taken. 29
" What kind of court decision will trigger the 180-day exclusivity? Exclusivity can
be triggered by a decision in a declaratory judgment action brought by the generic
manufacturer, including, for example, dismissal of that lawsuit for lack of case or
controversy when the patent holder admits to noninfringement. 0
* Can there be separate exclusivity periods for different ANDA applicants who
filed paragraph IV certifications as to different listed patents for the same inno-
vator drug product, and for different applicants for different dosages of the
same innovator drug product? Yes. One generic manufacturer may hold exclu-
sivity for one dosage strength, while a different manufacturer holds exclusivity
for a different dosage strength.31 Similarly, tablet forms and capsule forms of the
same drug are eligible for separate 180-day exclusivity periods. If products are
listed separately in the Orange Book, they are eligible for separate exclusivity
periods.
" How do 180-day exclusivity and pediatric exclusivity interact? If a pioneer earns
six months of pediatric exclusivity, the first generic applicant's ANDA is approved
effective the first day after conclusion of that exclusivity, and the 180 days begin to
run at that point. The terms are consecutive.
3 2
" Are 180-day exclusivity rights waivable and/or transferable? Yes. The first ge-
neric may waive its 180-day exclusivity rights in favor of another generic applicant
(or in favor of no generic), for consideration.33 In some instances, the consideration
has been a royalty stream that would continue even after exclusivity expired.
* Will marketing by the first generic of the pioneer's product under a private ge-
neric label satisfy the commercial marketing trigger? Yes.34
27 64 Fed. Reg. 42,873 (Aug. 6, 1999) (proposed regulations).
28 Mova v. Shalala, 140 F.3d 1060 (D.C. Cir. 1998); FDA, Guidance for Industry, 180-Day
Generic Drug Exclusivity Under the Hatch-Waxman Amendments to the Federal Food, Drug, and
Cosmetic Act (June 1998).
29 Pub. L. No. 108-173, § 1101(b)(3).
10 Teva Pharm., USA, Inc. v. FDA, 182 F.3d 1003 (D.C. Cir. 1999).
31 Apotex v. Shalala, 53 F. Supp. 2d 454 (D.D.C. 1999), aff'd, 1999 WL 956686 (D.C. Cir.
1999).
32 21 U.S.C. § 355A(k) (added by the Best Pharmaceuticals for Children Act).
33 See, e.g., 64 Fed. Reg. 42,873, 42,881 (Aug. 6, 1999); Boehringer Ingelheim Corp. v. Shalala,
993 F. Supp. 1 (D.D.C. 1997).
34 See Mylan Pharm., Inc. v. Thompson, 207 F. Supp. 2d 476 (N.D. W. Va. 2001).
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III. A HISTORY OF THE 1984 180-DAY EXCLUSIVITY PROVISION
A. 1984: Enactment
There were no changes to the 180-day exclusivity provision between its introduction
and the passage of the Hatch-Waxman Amendments.35 As enacted in 1984, the legisla-
tion provided that:
If the [ANDA] contains a certification described in subclause (IV) of para-
graph (2)(A)(vii) [otherwise known as a "paragraph IV certification"] and is for
a drug for which a previous application has been submitted under this subsec-
tion continuing [sic "containing"] such a certification, the application shall be
made effective not earlier than one hundred and eighty days after-(I) the date
the Secretary receives notice from the applicant under the previous application
of the first commercial marketing of the drug under the previous application, or
(II) the date of a decision of a court in an action described in clause (iii) holding
the patent which is the subject of the certification to be invalid or not infringed,
whichever is earlier.
36
Put another way, the first generic applicant to file an ANDA containing a paragraph IV
certification was to be awarded 180 days of marketing exclusivity, during which FDA
could not approve a subsequent ANDA with a paragraph IV certification for the same
drug product. The exclusivity period would be calculated from either the date of the first
commercial marketing of the generic drug product or the date of a court decision declar-
ing the patent invalid or not infringed, whichever was sooner.
The legislative history of the provision is sparse. Indeed, the provision is mentioned
only twice in the final House Report. Part 1 explains that:
If an ANDA certifying patent invalidity or non-infringement is filed subse-
quent to an ANDA for the same listed drug that has made the same certifica-
tion of invalidity or non-infringement, paragraph (4)(B)(iv) provides that the
approval of the subsequent ANDA may not be made effective sooner than 180
days after the previous applicant has begun commercial marketing, or the date
on which the court holds the patent invalid or not infringed, whichever occurs
first. In the event of multiple ANDAs certifying patent invalidity or non-in-
fringement, the courts should employ the existing rules for multidistrict litiga-
tion, when appropriate, to avoid hardship on the parties and witnesses and to
promote the just and efficient conduct of the patent infringement actions.37
31 The original language was introduced as part of Waxman's amendment to H.R. 3605, as
considered by the House Committee on Energy and Commerce, at 11. It can be found in S. 2926, as
placed on the Senate Calendar, at 13-14, and in H.R. 3605, as placed on the House Union Calendar,
at 14. The as-enacted version can be found at 98 Stat. 1589.
36 21 U.S.C. § 355(j)(5)(B)(iv). The concept of a "court decision" was used in two places in
section 5050) of the FDCA. First, the patent-owner is entitled to a 30-month stay on approval of an
ANDA that is the subject of patent infringement litigation except if "before the expiration of such
period the court decides that such patent is invalid or not infringed, the approval will be made
effective on the date of the court decision." Id. § 355(j)(5)(B)(iii)(1). Second, 180-day generic drug
exclusivity was to begin on either: 1) the date of first commercial marketing or 2) the date of a
decision of a court holding the patent which is the subject of the paragraph IV certification to be
invalid or not infringed, whichever is earlier. Id. § 355(j)(5)(B)(iv). Both provisions were amended by
Congress in the MMA. The court decision trigger for 180-day exclusivity was dropped altogether.
7 H.R. REP. No. 98-857, pt. 1, at 28 (June 21, 1984).
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Part 2 of the House Report essentially repeats the first sentence:
If an ANDA certifying patent invalidity or non-infringement is filed subse-
quent to an ANDA for the same listed drug that has made a similar certification,
clause (iv) provides that the approval of the subsequent ANDA can be made
effective [no] sooner than 180 days after the previous applicant has begun
commercial marketing, or the date on which the court rules the patent invalid or
not infringed, whichever occurs first.38
Neither passage offers insight into the interpretive issues that arose between 1984
and 2003.
B. 1994: FDA's Implementing Regulations
FDA was slow to issue regulations implementing the 180-day exclusivity provision.
The agency proposed regulations to implement the 1984 legislation in 1989, but final
regulations on the 180-day provision did not issue until October 1994.39 Few changes
were made between issuance of the proposed rule and issuance of the final rule.
The final regulation, printed at 21 C.F.R. § 314.107(c) (1994), stated that if an ANDA
contained a paragraph IV certification and was for a generic copy of the same listed drug
"for which one or more substantially complete abbreviated new drug applications were
previously submitted" containing a paragraph IV certification, and "the applicant sub-
mitting the first application has successfully defended against a suit for patent infringe-
ment brought within 45 days of the patent owner's receipt of notice," then approval of
the second ANDA would be made effective no sooner than the earlier of 1) the date the
first applicant "first commences commercial marketing of its drug product" or 2) the date
"of a decision of the court holding the relevant patent invalid, unenforceable, or not
infringed."'
The regulation clarified that the "applicant submitting the first application" is the
applicant that submits an application that both 1) is substantially complete and 2)
contains a paragraph IV certification, prior to the submission of any other application
for the same listed drug that both is substantially complete and contains the same
certification. A "substantially complete" application contains "the results of any re-
quired bioequivalence studies, or, if applicable, a request for a waiver of such stud-
ies."'" The regulation further stated that if the agency concluded that the first applicant
was "not actively pursuing approval" of its ANDA, FDA would make the approval of
subsequent abbreviated applications immediately effective if they were otherwise eli-
38 H.R. REP. No. 98-857, pt. 2, at 16 (Aug. 1, 1984).
39 54 Fed. Reg. 28,872 (July 10, 1989) (proposed rule); 59 Fed. Reg. 50,338 (Oct. 3, 1994) (final
rule). Before 1992, however, FDA granted exclusivity to only three applicants, and from 1992 to
1998, FDA did not grant exclusivity to any applicants. GENERIC DRUG ENTRY PRIOR TO PATENT ExPIRATION:
AN FTC STUDY 57 (July 2002). Each of the three applicants received exclusivity after successful
defense of a patent infringement suit. Id. at 60. By way of contrast, 31 applicants obtained exclusiv-
ity between 1998 (when the "successful defense" requirement was invalidated) and the FTC's 2002
report. Id. In 19 of these 31 instances, exclusivity was triggered by commercial marketing. Id. at 58,
60. See id. at 60-63 for a more detailed discussion of these statistics.
4" The statute refers only to a decision holding the patent invalid or not infringed. FDA added
"unenforceable."
" In the preamble to the proposed regulation, FDA had added that a "required bioequivalence
study is one that meets any FDA guidance document or is otherwise reasonable in design and purports
to show that the drug product for which the applicant seeks exclusivity is bioequivalent to the listed
drug." 54 Fed. Reg. at 28,895. It does not include a protocol or a pilot study. Id.
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gible for immediately effective approval. Finally, the regulation stated that the first
applicant must, if sued for patent infringement, notify FDA of the date that it com-
mences commercial marketing of its drug product. "Commercial marketing" was defined
as "the first date of introduction or delivery for introduction into interstate commerce
outside the control of the manufacturer of a drug product." It did not include shipment
for investigational use or transfer of the drug product "for reasons other than sale
within the control of the manufacturer or application holder."42
FDA clarified a number of important points in the preamble to the final regulations.
First, FDA stated that a generic applicant would be entitled to exclusivity only when it
has itself been involved in a patent infringement lawsuit. To provide otherwise "would
provide a windfall to an applicant who has not devoted the considerable time and
money necessary for patent litigation."43 After the FDA Commissioner signed the Fed-
eral Register notice of the proposed regulations, but before its publication in the Fed-
eral Register, a federal district court reached a contrary conclusion. The agency ap-
pealed that decision, however, and the case was dismissed as moot before FDA con-
cluded the rulemaking. 4 In its final regulations, the agency stood by its earlier position.
Another court rejected the agency's position in 1998, 41 however, and the requirement
ceased to apply.
Second, in response to comments, FDA provided in the final rule that a generic
applicant would be entitled to exclusivity only if it had successfully defended a patent
infringement suit. Neither the court decision nor the commercial marketing trigger would
apply, unless and until the first applicant won its patent infringement suit.' To provide
otherwise would "create[] an incentive for frivolous claims of patent invalidity or
noninfringement.47 A federal district court invalidated the successful defense require-
ment in 1997,48 and FDA removed it from the regulation in 1998.49
Third, as it had in the preamble to the proposed rule, FDA stated that the court
decision activating the court decision trigger "must be a final decision from which no
appeal can be or has been taken."5 A federal district court disagreed in 2000.11 For
ANDAs filed after March 2000, therefore, "court" refers to the first court to decide the
patent is invalid, not infringed, or not enforceable.5 2
Fourth, rejecting concerns about so-called "file first fix later" practices on the part of
generic manufacturers, FDA declined to establish criteria to determine whether changes
to an ANDA have been so substantial that it can no longer be considered to have been
the first filed. Instead, the agency would rely on its decision in 1992 to no longer accept
42 59 Fed. Reg. at 50,367-68.
43 Id. at 50,352-53.
1 Inwood Labs., Inc. v. Young, 723 F. Supp. 1523 (D.D.C. 1989), vacated as moot, No. 89-5209
(D.C. Cir., Nov. 13, 1998). Inwood asked the court of appeals to declare the case moot when six
months had elapsed after the lower court enjoined FDA from approving another ANDA. See Inwood
Case May Not Set Precedent on Exclusivity, WASHINGTON DRUG LETTER, Oct. 30, 1989, at 2.
4 Purepac Pharm. Co. v. Friedman, 162 F.3d 1201 (D.C. Cir. 1998).
6 See Mova Pharm. Corp. v. Shalala, 140 F.3d 1060, 1069-70 (D.C. Cir. 1998) (discussing FDA's
interpretation in 1994).
47 59 Fed. Reg. at 50,353.
" Mova Pharm. Corp. v. Shalala, 955 F. Supp. 128 (D.D.C. 1997), aff'd, 140 F.3d 1060 (D.C.
Cir. 1998).
49 63 Fed. Reg. 59,710 (Nov. 5, 1998) (interim rule).
50 59 Fed. Reg. at 50,354; 54 Fed. Reg. at 28,895.
"' Mylan Pharm., Inc. v. Shalala, 81 F. Supp. 2d (D.D.C. 2000).
52 FDA, Guidance for Industry, Court Decisions, ANDA Approvals, and 180-Day Exclusivity
Under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act (Mar. 2000).
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ANDAs lacking complete bioequivalence study data (if such data are required for ap-
proval) and use a "case-by-case approach" to ANDA changes. 3
C. 1997 Mova and Boehringer
1. Mova (The "Successful Defense" Case)
In January 1997, a federal district court invalidated the successful defense require-
ment.5 4 The events leading up to that decision began in December 1994, when Mova
Pharmaceutical Corporation filed an ANDA with a paragraph IV certification to market a
generic version of micronized glyburide, a diabetes drug patented by Pharmacia &
Upjohn. Pharmacia sued Mova for infringing its patent. In November 1995, while Mova
was engaged in that litigation, Mylan Pharmaceuticals Inc. filed an ANDA for the same
product. Although it originally included a paragraph Ill certification, Mylan amended its
ANDA, in August 1996, to contain a paragraph IV certification. Pharmacia declined to
sue, and FDA approved Mylan's application on December 19, 1996.11 FDA reasoned
that Mova's exclusivity did not bar approval of the Mylan ANDA, because Mova had
not yet successfully defended against Pharmacia's suit.
On December 26, 1996, Mova brought suit to compel FDA to delay the effective date
of its approval of Mylan's product until 180 days after the earlier of the date Mova won
its lawsuit or the date it began to market its product. Mova challenged the successful
defense regulation as contrary to the plain language of the statute. The district court
found that Mova had a very high likelihood of success on the merits of its claim and
granted a preliminary injunction.5 6
In 1998, the D.C. Circuit affirmed the district court's holding.57 Although FDA argued
that its successful defense requirement furthered the intent of Congress, the court dis-
agreed. The successful defense requirement, the court wrote, is "gravely inconsistent
with the text and structure of the statute."58 FDA's construction of the statute meant that
the first ANDA applicant could never benefit from that trigger. The D.C. Circuit explained,
The commercial-marketing trigger seems intended to insure that, if a first ANDA
applicant chooses to begin marketing its product before it has won its patent-
infringement suit, the 180-day exclusivity period will begin to run immediately.
Under the FDA's regulation, however, the 180-day exclusivity period is only
available to an applicant who has already "successfully defended against a
suit for patent infringement."59
Its practical effect, the court wrote, is "to write the commercial-marketing trigger out of
the statute." 6 The court recognized the problem, raised by Mylan, that the statutory
53 59 Fed. Reg. at 50,354. Although FDA had been requiring complete study data since 1992, it
commented in the preamble to the final rule that "[a] decision by the agency after receipt of an
application that the bioequivalence information is inadequate for approval does not necessarily mean
that the application was not substantially complete at the time of submission." Id. This effectively
undermined the 1992 solution to what FDA itself referred to as a "significant and unwarranted
expenditure of resources in reviewing applications that had little potential for approval." Id.
5 Mova Pharm. Corp. v. Shalala, 955 F. Supp. 128 (D.D.C. 1997).
I Id. at 130.
56 Mova Pharm. Corp. v. Shalala, 955 E Supp. 128 (D.D.C. 1997).
17 Mova Pharm. Corp. v. Shalala, 140 E3d 1060 (D.C. Cir. 1998).
11 Id. at 1069.
59 Id. at 1069-70.
60 Id. at 1069. The court reasoned that "if the first applicant begins marketing its product before
it wins its infringement suit, the 180 days of exclusivity do not begin to run; other applicants remain
eligible for FDA approval to begin marketing their products, at least up to the date that the first
applicant wins the infringement action." Id. at 1070.
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scheme might penalize a meritorious second ANDA applicant.6' Nevertheless, the court
found that the successful defense requirement was too "blunt an instrument" to ad-
dress that problem.62 Thus, the regulation was invalid. Mova accordingly established
that the first generic need not successfully defend a patent infringement suit in order to
enjoy the benefits of 180-day exclusivity.63
2. Boehringer Ingelheim (The "Transfer of Exclusivity" Case)
In Boehringer Ingelheim Corp. v. Shalala, a federal district court upheld FDA's
decision to approve an ANDA filed by a second applicant who had purchased 180-day
exclusivity from the first applicant.' The court noted that the Hatch-Waxman Amend-
ments are silent on the question of transferability of 180-day exclusivity. FDA's decision
to allow transfer in this instance, therefore, was well within the zone of the agency's
discretion. 65 FDA would restate its position that 180-day exclusivity rights are transfer-
able for consideration in proposed regulations published in 1999, 66 and the agency has
continued to approve ANDAs filed by applicants who have purchased the exclusivity
rights of the first to file. 67 The availability of a transfer option and the lack of any sort of
forfeiture provision led to absurd results, however, as in 2002 when the first applicant to
file a substantially complete ANDA for generic Prilosec® (omeprazole) was found to
infringe the sponsor's patents and was able, nevertheless, to block market entry by a
noninfringing ANDA applicant until that second applicant agreed to pay a royalty
stream for the life of its drug product.
68
D. 1998: Granutec, a Guidance to Industry, an Interim Rule, and Purepac I
1. Granutec (A "Successful Defense" Case)
After the district court in Mova found that FDA's successful defense regulation was
invalid,69 FDA decided to cease enforcing the regulation pending appeal. During the
pendency of that appeal, the Fourth Circuit, too, invalidated FDA's successful defense
requirement. 70
61 Id. at 1072.
62 Id. at 1074.
63 In dicta, the court also approved as "elegant and textually persuasive" an argument made by
Teva Pharmaceutical (as amicus curiae) that the court-decision trigger may be satisfied by any
decision of a court holding the patent invalid or not infringed-including suits not brought by the
patent holder, such as a declaratory judgment action by the second ANDA applicant. Id. at 1072-73.
The court noted, however, that it "seems odd to reward the first applicant if some later applicant was
the party that actually prevailed in the patent-infringement litigation." Id. at 1073.
64 993 F Supp. I (D.D.C. 1997). Neither the court's opinion nor trade press disclosed the terms
of the agreement, but it is reasonable to assume consideration was involved. See, e.g., Novopharm
Marketing Generic Rantidine Through Agreement with Genpharm; Three-Week Delay Brings Glaxo
$100 Mil. in Additional Zantac Sales, F-D-C REP. ("The Pink Sheet"), Aug. 4, 1997, at 3.
65 See Chevron v. Natural Resources Defense Council, 467 U.S. 837 (1984).
66 64 Fed. Reg. 42,873, 42,881 (Aug. 6, 1999).
67 FTC STmUY supra note 7, at 36 ("For 6 out of 68 drug products in which there was more than one
generic applicant, the first and second generic applicant entered into agreements related to generic market
entry. In 4 of these agreements, one of the main provisions specified which generic applicant had or
retained rights to the 180-day exclusivity."); id. ("In 1 agreement, the first generic applicant relinquished
its rights to 180-day exclusivity for a $35 million license and royalty payment based on the second generic
applicant's sales for a period of 7 years.").
68 See Andrx Altocor Sales Force Expanded 50%; Generic Prilosec Charge is $41 Mil., F-D-C
REP. ("The Pink Sheet"), Nov. 4, 2002, at 4.
69 955 F. Supp. 128 (D.D.C. 1997).
70 Granutec, Inc. v. Shalala, 139 F.3d 889, 1998 WL 153410. (4th Cir. 1998) (unpublished).
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In this case, Genpharm Inc. had filed an ANDA with a paragraph IV certification for
generic ranitidine (Form 2) in February 1991-the first to file. GlaxoWellcome, Inc., the
owner of the patent for ranitidine, sued Genpharm and prevailed.7 In 1996, Genpharm
filed an ANDA with a Paragraph IV certification for generic ranitidine (Form 1).
GlaxoWellcome again sued,72 but that case was still pending when Granutec was de-
cided. In April 1994, in the interim between the two Genpharm ANDAs, Granutec, Inc.
filed a Paragraph IV ANDA for generic ranitidine (Form 1). GlaxoWellcome brought suit,
but Granutec prevailed.73
GlaxoWellcome and Granutec then entered into a licensing agreement for the final
fifteen days of the patent on Zantac®, and Granutec sought FDA approval for its generic
version beginning July 10, 1997. FDA refused approval, stating that the 180-day exclu-
sivity period had been triggered on March 3, 1997, when the Federal Circuit had found,
in an unrelated case, that Boehringer Ingelheim Corp.'s version of generic ranitidine did
not infringe Glaxo's patent. 74 Because Genpharm had filed the first ANDA for generic
ranitidine, and because FDA had suspended the successful defense requirement after
the district court decision in Mova, FDA concluded that Genpharm was entitled to
exclusivity. (Genpharm, however, did not have final approval of its ANDA.).
Granutec then brought suit, arguing that FDA's refusal to enforce the successful
defense requirement was arbitrary and capricious. The district court agreed and issued
an injunction requiring FDA to adhere to the successful defense requirement.75 This
would effectively mean that no company would be entitled to exclusivity. The Fourth
Circuit reversed, finding that the statute did not require a successful defense against a
patent infringement suit. Genpharm was entitled to exclusivity.76 The decision was not
published, however, and under Fourth Circuit rules, the court of appeals could not cite
it in any subsequent published opinion or unpublished disposition.
77
2. A Guidance to Industry and an Interim Rule ("Successful Defense")
In June 1998, shortly after the Granutec decision (April 3) and the appellate decision
in Mova (April 14), FDA published a guidance for industry.7" This guidance detailed a
new approach to 180-day exclusivity in light of the court decisions. FDA announced its
intent to "formally" remove the successful defense requirement from the regulation and
to conduct a rulemaking proceeding to issue new regulations. 79 In the meantime, FDA
stated, it would "regulate directly from the statute" and "make decisions on 180-day
generic drug exclusivity on a case-by-case basis."1° Thus, the agency would inform the
first applicant to submit a substantially complete abbreviated application with a para-
graph IV certification that, as the first applicant, it was eligible for 180 days of market
exclusivity, even though it had not been sued for patent infringement.8' In November,
71 Id. at *4.
72 Id.
73 Id.
14 Id. at *5, discussing Glaxo, Inc. v. Boehringer Ingelheim Corp., 954 F. Supp. 469 (D. Conn.
1996), judgment entered by 962 F. Supp. 295 (D. Conn. 1997), aff'd, No. 97-1283, 1997 WL
355339 (Fed. Cir. June 4, 1997).
71 1998 WL 153410 at *5.
76 Id. at *7.
71 See Court of Appeals for the Fourth Circuit Rule 36(b).
78 See FDA, Guidance for Industry, 180-Day Generic Drug Exclusivity Under the Hatch-Waxman
Amendments to the Federal Food, Drug, and Cosmetic Act (June 1998).
79 Id. at 4.
80 Id.
11 Id. at 5.
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FDA published an interim rule, eliminating the successful defense requirement of 21
C.F.R. § 314.107(c)(1). 2 The agency also made a conforming change to 21 C.F.R.
§ 214.107(c)(4), by deleting the phrase "if sued for patent infringement."83
3. Purepac I (The "First Generic Need Not Be Sued" Case)
In December 1998, the D.C. Circuit confirmed that the first generic need not be sued
for patent infringement.' TorPharm, a division of Apotex, Inc., was the first to file an
ANDA for a generic version of Ticlid® (ticlopidine hydrochloride). TorPharm's ANDA
contained a paragraph IV certification. No one brought a patent infringement suit against
TorPharm, however, and when the Purepac case was litigated, FDA had not yet finally
approved TorPharm's ANDA. Thus, the 180-day clock had not yet begun to run.
FDA tentatively approved Purepac Pharmaceutical Company's subsequent ANDA,
but withheld final approval pending TorPharm's final approval, commercial marketing,
and expiry of its 180-day exclusivity. Purepac sued for an injunction claiming that
TorPharm was not entitled to exclusivity because it had not been sued for infringe-
ment.85 The court concluded that FDA's "revised system for granting exclusivity" was
consistent with the statute and the Mova decision.86 The statute does not require the
first applicant to be sued in order to benefit from market exclusivity. Thus, FDA could
withhold final approval of the Purepac ANDA until TorPharm had commercially mar-
keted for 180 days.
E. 1999: The Apotex and Teva Decisions, a Response to Citizen
Petitions, and Proposed Regulations
1. The Apotex Decision ("Separate Exclusivity Periods")
In Apotex v. Shalala, the D.C. Circuit resolved the question whether different dos-
ages of a drug are eligible for separate 180-day exclusivity periods. 7 Glaxo held the
patent and NDA for ranitidine hydrochloride, which it markets under the trade name
"Zantac®." Among the ranitidine hydrochloride products sold by Glaxo were 150 mg
and 300 mg tablets, both prescription drug products intended for the treatment of ulcers,
and 75 rug tablets, sold over-the-counter (OTC) for the treatment of heartburn. Genpharm
was the first to file for the 150/300 mgs, and its exclusivity ran from March 3 to August
29, 1997. FDA had since approved additional ANDAs. NovoPharm Ltd. was the first to
file on the 75 mg OTC product and was eligible for 180-day exclusivity. Apotex sought
immediate approval of its own 75 mg tablets, however, on the theory that FDA may not
grant exclusivity periods for ANDA applications that concern the same patents in-
volved in previously-approved drugs of different strengths. The district court dis-
agreed, holding that permitting separate exclusivity periods for separate drug strengths
is consistent with the statute, which requires that an ANDA must contain, among other
things, "information to show that the route of administration, the dosage form, and the
strength of the new drug are the same as those of the listed drug." 88 (Each strength has
82 63 Fed. Reg. 59,710 (Nov. 5, 1998).
83 Id. at 59,712.
84 Purepac Pharm. Co. v. Friedman, 162 F.3d 1201 (D.C. Cir. 1998).
15 162 F.3d at 1202.
86 Id. at 1204.
87 53 F. Supp. 2d 454 (D.D.C 1999), aff'd, 1999 WL 956686 (D.C. Cir. 1999).
18 Id. at 456 (emphasis added).
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a separate listing in the Orange Book.) For similar reasons, tablet forms and capsule
forms of the same drug were to be eligible for separate 180-day exclusivity.89
2. The Teva Decision (Meaning of a "Court Decision")
In Teva Pharmaceuticals,9 the D.C. Circuit ruled on the meaning of "court deci-
sion." On June 20, 1997, Teva Pharmaceuticals, USA, Inc. filed an ANDA for ticlopidine
tablets, a generic version of Ticlid®. Teva was a subsequent applicant, not the first
generic applicant. Teva then sued the patent holder, Syntex (U.S.A.), Inc., in the Central
District of California for a declaratory judgment of noninfringement. 1 After Syntex
admitted that Teva's ANDA did not infringe its patent, the California court dismissed
the suit for lack of subject matter jurisdiction.92
On October 29, 1998, FDA tentatively approved Teva's ANDA. FDA informed Teva,
however, that because there was a prior ANDA applicant, and neither commercial mar-
keting nor a court decision had occurred, its application was ineligible for final approval.
Teva argued, to no avail, that the California court's dismissal of its declaratory judgment
suit against Syntex satisfied the "court decision" requirement, triggering the other
company's exclusivity. Teva then brought suit in federal district court in the District of
Columbia, seeking to have its ANDA approved effective 180 days after the California
court dismissed the declaratory judgment suit. The district court upheld FDA's decision
and denied injunctive relief.93 The D.C. Circuit reversed, holding that the dismissal by
the California court was the functional equivalent of a final decision of noninfringement.
FDA's unexplained refusal to recognize it as such was arbitrary. The refusal also was
contrary to the FDCA, FDA's guidance document, and FDA's position in Granutec.94
The discussion in Teva addresses several points. First, any court decision with "pre-
clusive effect," even a dismissal of a declaratory judgment action, can trigger exclusiv-
ity. In this case, dismissal of the California case was a triggering court decision because
it precluded the patent holder from suing Teva for patent infringement. "A 'decision'
can take several forms," the court wrote "including final judgment after a full trial,
summary judgment or partial summary judgment, or even dismissal for failure to state a
cause of action." 95 Second, although the statute provides that exclusivity dates to a
decision that the patent is invalid or not infringed, FDA's regulations, since 1994, have
said "invalid, unenforceable, or not infringed." The D.C. Circuit rejected the argument
that unenforceability (in the regulation) and estoppel (in the case at hand) should be
treated differently from invalidity and noninfringement.96 Third, the case confirms that
89 See, e.g., Mylan Pharm., Inc. v. Shalala, 81 F. Supp. 2d at 30, 35 n.8 (D.D.C. 2000) ("The
tablet and capsule forms of the drug, however, are distinct products for FDA purposes and are thus
each eligible for their own exclusivity.") (citing Apotex).
I Teva Pharm., USA, Inc. v. FDA, 182 F.3d 1003 (D.C. Cir. 1999).
91 Id. at 1006.
92 Id.
13 Id. at 1007.
14 Id. at 1010-ll.
11 Id. at 1007-08. Although Congress eliminated the court decision trigger for exclusivity in the
MMA of 2003, it established a new court decision trigger for forfeiture of exclusivity, and confirmed
this interpretation of "court decision" for the purposes of this new provision. See 149 CONG. REc.
S15885 (daily ed. Nov. 25, 2003) (statement of Sen. Kennedy) ("We do intend that a court decision
like the one in the D.C. Circuit's 1999 decision in Teva v. Shalala-a decision dismissing a declaratory
judgment action for lack of subject matter jurisdiction because the patent owner has represented that
the patent is not infringed-will count as a court decision under the new 'failure to market' provi-
sion."). Elimination of the court decision trigger was prospective only. Congress also made a retroac-
tive change, dictating that the relevant court for ANDAs subject to the old rules is the appellate court.
96 Teva, 182 F.3d at 1009.
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the court decision that triggers exclusivity need not involve the first generic; instead, it
may involve the patent holder and another ANDA applicant. Thus, if the pioneer has
sued subsequent ANDA filers for patent infringement on the same drug, any decision
of a district court finding the patent invalid, not infringed, or unenforceable in any of
those cases will trigger exclusivity.
3. A Response to Citizen Petitions ("Multiple Exclusivity")
On August 2, 1999, in response to two citizen petitions, FDA decided that multiple
generic applicants may hold exclusivity simultaneously. American Pharmaceutical Part-
ners Inc. (APP) and Pharmachemie B.V. each requested that FDA stay approval of any
ANDA other than their own for generic versions of Platinol-AQ®. Pharmachemie had
filed the first substantially complete ANDA with a paragraph IV certification for the one
patent. The patent holder did not file suit on this one, and it expired. APP filed the first
substantially complete ANDA with a paragraph IV certification for a different patent.
Pharmachemie then did the same thing. Bristol-Myers Squibb filed suit against both
companies-each of whom argued that it had been the first to file a paragraph IV
certification.
In response, FDA defined the controversy as "whether multiple ANDA applicants
each can be eligible for 180-day exclusivity because each applicant was the first to file a
paragraph IV certification as to a different patent for the listed drug."97 Although FDA
intended to issue new proposed rules, "until such new regulations are final, FDA's deter-
minations are governed by the existing regulations and the relevant provisions of the
statute. 98 FDA determined that both applicants could be entitled to exclusivity. The
issue was "whether one or more substantially complete ANDAs were submitted that
contained a certification that the same patent was invalid, not enforceable, or would not be
infringed. Therefore, under the current regulations, eligibility for exclusivity is to be deter-
mined on a patent-by-patent basis."" FDA's response makes it clear that the agency
thought this result was unworkable and that FDA intended to address this issue in new
regulations. In this particular instance, however, FDA granted exclusivity only to APP.
The agency reasoned that Pharmachemie's exclusivity had terminated automatically when
the patent in question expired. This theory was challenged in a citizen petition filed by
TorPharm,1 ° but the company withdrew the petition before FDA answered.
4. Proposed Regulations
Four days later, on August 6, FDA proposed regulations to alter substantially the
180-day exclusivity rules. 10 1 This proposal would be withdrawn in 2002, but FDA never-
theless implemented a number of the policies that the proposal represented.
First, the proposed regulations continued to state that, in order to be entitled to 180-
day exclusivity, an ANDA applicant must be the first to file a substantially complete
ANDA with a paragraph IV certification. An ANDA was not substantially complete if
FDA determined that the required bioequivalence data failed to meet FDA standards. If
FDA found the bioequivalence studies to be deficient, that applicant would lose its
97 See FDA Response to APP and Pharmachemie Citizen's Petitions, 99P-1271/PDN1 (Aug. 2,
1999) (on file with author), at 3.
91 Id. at 4.
99 Id.
10 TorPharm Citizen's Petition, 99P-5317 (Dec. 7, 1999) (on file with author).
101 64 Fed. Reg. 42,873 (Aug. 6, 1999).
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exclusivity, and no other applicant would be granted exclusivity. As this suggests, there
was no "rolling exclusivity.""1 2 Thus, for example, if the first generic withdrew its appli-
cation, no subsequent applicant would be granted exclusivity. If the first generic did not
perfect its right to the 180-day period (e.g., if it lost the patent infringement case),
exclusivity would not roll over to the next-filed ANDA. This aspect of the August 1999
regulations was not new.
Second, multiple applicants could share exclusivity for a drug. All ANDAs for a
particular drug, with paragraph IV certifications, received on the same day would be
eligible for exclusivity, so long as no ANDAs were filed on a previous day. This aspect
of the August 1999 proposal continued to be agency policy after withdrawal of the
proposal and was restated in its July 2003 guidance.
10 3
Third, FDA proposed a new "triggering period" for 180-day exclusivity. Under this
proposal, once a subsequent generic received tentative approval for its generic drug
from FDA (such that the exclusivity was the only obstacle it faced for final approval), a
new 180-day triggering period (not to be confused with the 180-day exclusivity period)
would begin to run."°4 Within 180 days, one of the two 180-day exclusivity period
triggering events would need to occur, or the first generic would lose its exclusivity. 5
Because FDA took the position that there was no rolling exclusivity, no other generic
would be eligible. This new triggering period would have served the same purpose as a
provision in the regulations stating that a first generic would lose its exclusivity if it did
not "actively pursue" approval of its ANDA. With the 2002 withdrawal of the proposed
regulations, this idea was never implemented.
Fourth, after occurrence of one of the triggering events-but only after that event-
a first generic would have been permitted to transfer its rights to another company. 106
FDA noted that transfer can be particularly useful when a subsequent generic wins its
patent suit with the pioneer before the first generic's suit goes to trial. 7 Prior to occur-
rence of a triggering event, however, the first generic would not have been permitted to
transfer its exclusivity rights. It could waive its exclusivity entirely, permitting FDA to
approve subsequent ANDAs, but it could not waive its rights in favor of a particular
generic manufacturer (i.e., sell its rights) until the occurrence of a triggering event.
FDA's informal position to permit transfers of exclusivity already had withstood court
scrutiny,1 °8 but with the 2002 withdrawal of the proposed regulations, the use of a
triggering event as a threshold requirement would not be implemented.
F. 2000: Mylan I, a Guidance for Industry and Interim Regulations,
and Mylan II
1. Mylan I ("Court Decision" and "Transfer of Exclusivity")
In Mylan I, a federal district court rejected FDA's position that the triggering event is
"either the date that a district court decision is affirmed by the Federal Circuit, or the date
102 Id. at 42,873.
103 Same-day patent challenges generally occur when four years of a five-year new molecular
entity exclusivity period have expired, permitting the submission, on a particular date, of ANDAs
containing paragraph IV certifications. See 21 U.S.C. § 355(j)(5)(D)(ii).
101 64 Fed. Reg. at 42,878.
105 Id.
106 Id. at 42,881.
107 Id.
108 See Boehringer Ingeiheim Corp. v. Shalala, 993 F. Supp. I (D.D.C. 1997) (upholding FDA
approval of second ANDA filer who had purchased 180-day exclusivity from first generic).
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on which the time for filing an appeal has lapsed."'" In other words, the court held that
"decision of a court" includes "the decision of a United States district court regardless
of whether that decision is appealed."'"0 The rule that resulted, therefore, was that the
first generic's 180-day exclusivity period begins to run on the date of a district court
decision finding invalidity, unenforceability, or noninfringement. The court also con-
firmed that exclusivity may be transferred separately from the ANDA, writing that
"[e]xclusivity periods are a transferable commodity which can be waived in favor of
another generic manufacturer for a substantial price."'I
2. A Guidance for Industry and Interim Regulations ("Court
Decision ")
In March 2000, FDA issued a guidance document responding to the Mylan I decision. 2
In the guidance document, FDA stated that it would interpret the term "court" to mean "the
first court that renders a decision finding the patent at issue invalid, unenforceable, or not
infringed."" 3 After such a court decision, FDA would approve the first generic as of the date
of the decision. Neither a stay nor a reversal of this decision would revoke approval of the
first generic's ANDA or its 180-day exclusivity. If a district court found patent infringement,
however, and that ruling was reversed by the Federal Circuit, the first generic's ANDA would
be approved and the 180-day exclusivity would start "on the date the district court issues a
judgment that the patent is invalid, unenforceable, or not infringed pursuant to a mandate
issued by a court of appeals."' 14 FDA agreed that this could compromise companies that
had developed marketing strategies in reliance on the old definition of court decision. FDA,
therefore, would apply the new guidance prospectively. The new definition of court would
apply only to ANDAs filed after March 30,2000.11 In July 2000, FDA published interim
regulations amending the definition of "court decision" as detailed in the March 2000 guid-
ance and consistent with the Mylan decision."6
3. Mylan II ("Court Decision" and "Loss of Exclusivity")
In Mylan II, the district court determined that a first generic could lose its exclusivity
if it were obliged to amend its certification from a paragraph IV to a paragraph Ill. The
Southern District of New York had invalidated the tamoxifen patent held by Imperial
Chemicals Industries, PLC, but that decision was subsequently appealed and vacated
pursuant to a settlement agreement between Imperial and the generic manufacturer (Barr
Laboratories)."v Pursuant to the settlement, Barr amended its ANDA from a paragraph
IV to a paragraph Ed certification. Barr also obtained a license to market the product prior
to patent expiry. FDA declined to treat the New York decision as a "court decision" for
purposes of exclusivity and instead agreed with Barr that its exclusivity was intact.
In Mylan II, the D.C. District Court held that Barr had waived eligibility for 180-day
exclusivity, explaining that once a company changes its certification, the ANDA is no
19 Mylan Pharm. Inc. v. Shalala, 81 F. Supp. 2d 30, 41-42 (D.D.C. 2000).
110 Id. at 47.
"I Id. at 42.
112 FDA, Guidance for Industry, Court Decisions, ANDA Approvals, and 180-Day Exclusivity
Under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act (Mar. 2000),
available at www.fda.gov/cder/guidance/3569fnl.pdf (last accessed May 17, 2004).
113 Id. at 4.
114 Id.
115 Id.
116 5 Fed. Reg. 43,233 (July 13, 2000).
W1 Mylan Pharm. Inc. v. Henney, 94 F. Supp. 2d 36 (D.D.C. 2000).
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longer considered to have "contained" a paragraph IV certification."5 This meant Barr
was no longer eligible for exclusivity, so FDA could approve Mylan's ANDA. The court
also noted that "a decision of a court" meant all court decisions, whether subsequently
vacated, settled, appealed, or otherwise mooted." 9
G. 2001: Mylan HI and the Best Pharmaceuticals for Children Act
1. Mylan III ("Commercial Marketing Trigger")
In Mylan III, a district court in West Virginia held, among other things, that a generic
manufacturer begins commercial marketing, and thereby starts the 180-day clock, even
when it sells a private label version of the innovator's product, rather than the product
that is the subject of its ANDA. 20
In April 1997, Mylan submitted an ANDA with a paragraph IV certification for 30 mg
dosages of nifedipine. It was, therefore, the first generic. The pioneer company, Pfizer
Inc., sued Mylan for infringement and the parties settled in February 2000. Although the
settlement terms were not made public or given to the court, Pfizer apparently licensed
Mylan to sell a private label version of its own 30 mg, 60 mg, and 90 mg nifedipine
products. Pfizer also may have permitted Mylan to market its own 30 mg product under
its own ANDA, but Mylan never did so. Mylan claimed the settlement allowed it to
maintain its paragraph IV certification and never amended the paragraph IV certification
to a paragraph III certification.
After the settlement, Biovail Laboratories, Inc., a generic manufacturer aspiring to
market nifedipine, attempted without success to persuade Mylan to waive its 180-day
exclusivity. When this failed, Teva Pharmaceuticals USA, Inc. (its licensee) submitted a
citizen petition to FDA asking the agency to find either: a) the Mylan ANDA was not
eligible for exclusivity or b) any exclusivity had expired. 2 FDA responded in February
2001, agreeing on both grounds. 122 The agency reasoned, first, that the settlement
effectively turned Mylan's paragraph IV certification into a paragraph III certification,
and second, that the private label sales constituted commercial marketing and triggered
exclusivity.123 Because the 180 days had expired, FDA approved Biovail's ANDA.
Mylan brought suit. In the decision that resulted, Mylan III, the district court found
that FDA had been unreasonable on the first issue and reasonable on the second. The
court was not prepared to allow FDA unilaterally to deem the paragraph IV certification
to be a paragraph HI certification, particularly because Mylan had not amended the
certification in its ANDA. (The court distinguished the earlier Mylan II case on this
ground.) But the private label sales were commercial marketing, and thus the 180-day
period had expired. 24
11 Id. at 56-57. On May 24, 2001, Gary Buehler, Acting Director of FDA's Office of Generic
Drugs, confirmed this by telling the Senate Judiciary Committee that "Only an application containing
a paragraph IV certification may be eligible for exclusivity. If an applicant changes from a paragraph
IV certification to a paragraph III certification, for example upon losing its patent infringement
litigation, the ANDA will no longer be eligible for exclusivity." Competition in the Pharmaceutical
Marketplace: Antitrust Implications of Patent Settlements: Hearing Before the Senate Comm. on the
Judiciary, 107th Cong. 12 (2001) (statement of Gary Buehler, RPh).
19 Mylan 11, 94 F. Supp. 2d at 54.
120 Mylan Pharm., Inc. v. Thompson, 207 F. Supp. 2d 476 (N.D. W. Va. 2001).
"I Id. at 482.
122 Id.
123 Id.
11 Id. at 488. In the MMA of 2003, Congress amended the FDCA to provide that the generic
manufacturer's marketing of the listed drug would trigger exclusivity. See 21 U.S.C. § 355(j)(5)(B)(iv)(I).
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2. Best Pharmaceuticals for Children Act ("Relationship to Pediatric
Exclusivity ")
In May 2001, FDA sought public comment on whether pediatric exclusivity for an
innovator runs concurrently or consecutively with 180-day exclusivity for the first ge-
neric. 12 The agency evidently believed that the two exclusivity provisions run concur-
rently.26 At least one generic manufacturer challenged this assertion.
Barr was the first generic for Eli Lilly & Company's drug Prozac®. A district court
found infringement, but the Federal Circuit reversed and held the second of two chal-
lenged patents invalid, while upholding the first.'27 The upheld patent was not set to
expire until February 2001, followed by an additional six months of pediatric exclusivity.
Had the appellate court ordered the district court to enter a judgment of invalidity on the
second patent in September 2000, Barr's exclusivity would have started to run and
would have expired before Lilly's pediatric exclusivity was due to expire. Barr prepared
to challenge FDA's interpretation, but it turned out never to be necessary. The timing of
the Federal Circuit's denial of a petition for rehearing and the district court's resulting
judgment of invalidity (triggering Barr's 180 days) was such that pediatric exclusivity
already had expired. Congress resolved the issue, however, with the passage of the Best
Pharmaceuticals for Children Act (BPCA). 28
In the BPCA, Congress added section 505A(k) to the FDCA, which states that 180-
day exclusivity does not begin until an innovator's pediatric exclusivity has expired.
This ensures that generic drug manufacturers entitled to 180-day exclusivity do not
lose a portion of that exclusivity due to the overlap with the innovator's pediatric
exclusivity.
H. 2002: FTC Report and Withdrawal of Proposed Rule
1. The FTC Report
In July 2002, the FTC issued a report on its investigation of generic and innovator
practices that were alleged to impede generic market entry.'29 This report described anti-
trust law enforcement actions the FTC had taken against generic drug companies who had
allegedly entered into anticompetitive agreements while taking advantage of 180-day
exclusivity. For example, the FTC concluded that fourteen of twenty final settlements of
ANDA-related patent litigation during the time period of the study had the potential to
delay the start of the first generic's 180-day exclusivity.' In four instances, the FTC
concluded that the innovator had paid the first generic not to waive exclusivity and not to
enter the market during the life of the patent. This prevented the 180-day exclusivity from
ever starting and therefore kept all generics off the market until patent expiry. 3' If a
125 FDA Request for Comments, 66 Fed. Reg. 27,983 (May 21, 2001).
'2 See Barr Fluoxetine Will Have Two Months Exclusivity Under "Worst Case," F-D-C REP. ("The
Pink Sheet"), Mar. 12, 2001, at 3.
27 Eli Lilly & Co. v. Barr Labs. Inc., 222 F3d 973 (Fed. Cir. 2000).
1'28 Pub. L. No. 107-109, 115 Stat. 1408 (2002).
129 FTC STUDY supra note 7.
13o Id. at 26.
131 Id. at 31. FDA had supported its "successful defense" requirement in 1998 on the ground that
it would preclude results like this. An applicant that is not sued (e.g., because it signs an agreement with
the pioneer) would not have "successfully defended" and thus, under FDA's reasoning at the time,
would not be entitled to exclusivity. Under FDA's 1998 theory, this would permit, rather than
preclude, approval of subsequent applicants.
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subsequent ANDA applicant prevailed in a patent infringement case, of course, the 180-
day period would start. But the pioneer simply would avoid filing suit against that subse-
quent applicant.132 FTC investigations in this area became public in 1999, and there have
been no innovator-generic agreements of this nature since that time.'33 In two other
instances, the first generic marketed the pioneer's product under a private label.'34 As
noted, one district court has held this does trigger exclusivity.'35 In any event, the FI'C
recommended notification to the FTC and the U.S. Department of Justice (DoJ) of any
innovator-generic agreement relating in any way to 180-day exclusivity or the manufac-
ture, marketing, or sale of an innovator drug or its generic equivalent.
3 6
2. Withdrawal of Proposed Rule
In November 2002, FDA withdrew its August 1999 proposed rule.'37 "After careful
consideration of the comments," FDA wrote, "and the multiple court decisions affecting
the agency's interpretation of the provisions of the act relating to 180-day exclusivity
and ANDA approvals," the agency concluded that "it is appropriate to withdraw the
August 1999 proposed rule at this time."' 38 Thus, FDA "will continue to regulate di-
rectly from the statute and applicable FDA regulations to make 180-day exclusivity
decisions on an issue-by-issue basis."'
139
I. 2003: Purepac II, a Guidance Document, TorPharm, and Purepac III
1. Purepac II ("Controlling Date for Exclusivity Purposes" and
Little Section viii)
In Purepac v. Thompson, the U.S. District Court for the District of Columbia affirmed
an FDA decision that clarified when a generic applicant has submitted its paragraph IV
certification, for exclusivity purposes."' Purepac mailed its certification to FDA on the
patent in question on May 25, 2000, and FDA received the certification on May 26, 2000.
Purepac waited until June 13, however, to send notice to the NDA holder. TorPharm, in
contrast, mailed its certification on June 13, and FDA received TorPharm's certification
on June 16. TorPharm sent its notice to the NDA holder on the same day (June 13) that
it mailed its certification to the agency. FDA concluded that the penalty for Purepac's
failure to provide notice simultaneously with its certification, as required by 21 U.S.C.
§ 355(j)(2)(B)(iii) and 21 C.FR. § 314.95(d), should be postponement of the certification's
effective date-rather than nullification of the certification, as TorPharm had argued. 141
That date was still earlier than the effective date of TorPharm's certification, so FDA
132 Arguably, the subsequent generic could file a declaratory judgment action after the 45-day
window for a patent infringement suit, but it would be difficult to establish federal court jurisdiction if the
pioneer did not intend to sue.
'31 FTC STUDY, supra note 7, at viii.
's4 Id. at 25.
'M' Mylan Ill, 207 F. Supp. 2d at 488.
136 Id. at vi. Congress would include in the MMA a provision requiring this notification. See Pub.
L. No. 108-173, § 1112.
13 67 Fed. Reg. 66,593 (Nov. 1, 2002).
31 Id. at 66,594.
139 Id.
'4 Purepac Pharm. Co. v. Thompson, 354 F.3d 877 (D.C. Cir. 2004), aff'g TorPharm, Inc. v.
Thompson, 260 F. Supp. 2d 69 (D.D.C. 2003); see also TorPharm Rebuffed on Bid to Overturn FDA
Decision Awarding Exclusivity to Purepac, BNA PHARM. LAW & INDUSTRY REP., Jan. 23, 2004, at 85;
Appeals Court Backs FDA: Purepac Gets Gabapentin 180-Day Award, FDA WEEK, Jan. 23, 2004, at 3.
141 TorPharm v. Thompson, 260 F Supp. 2d at 79-81.
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found that only Purepac was eligible for exclusivity with regard to that patent. 142 The
district court found this to be a reasonable exercise of the agency's discretion.143 The
court also sustained FDA's decision that the operative date for the filing of an amended
certification is the day the certification is received by the agency, rather than the date
the certification is mailed by the applicant.'" The D.C. Circuit affirmed on January 20,
2004.145
Also at issue in this case was a patent that had been listed in the Orange Book and
then, after litigation, deemed by FDA to be ineligible for listing.'46 The generic applicant
who had filed a paragraph IV certification on the patent brought suit, seeking to retain
its exclusivity. The patent in question claimed a method of use of Neurontin®
(gabapentin)-the treatment of neurodegenerative diseases-for which the innovator
drug was not approved and for which the ANDA applicants could therefore not seek
approval. After litigation, a federal court determined that Purepac's "section viii" state-
ment as to this patent was appropriate.'47 TorPharm, however, had submitted a para-
graph IV certification on the patent. Under agency regulations, when a patent has been
the "subject of a lawsuit" based on a paragraph IV certification, it may be delisted only
if no ANDA applicant is entitled to exclusivity on the patent. 148 Under well-established
agency policy, however, where a section viii statement is proper, a paragraph IV certifi-
cation is not. FDA determined that -in light of the federal court ruling that a section viii
statement was appropriate-TorPharm's paragraph IV certification was improper; thus
eliminating TorPharm's eligibility for exclusivity. FDA also removed the patent from the
Orange Book, on the ground that it claimed a use the agency had not approved. No
company was entitled, therefore, to exclusivity on the patent. The district court found
FDA's actions to be reasonable and the D.C. Circuit affirmed. 149
2. A Guidance Document ("Multiple First Applicant")
In August 2000, Zenith Goldline Pharmaceuticals (now IVAX) petitioned FDA for a
determination that "all [ANDAs] containing a paragraph IV certification delivered to
FDA's Office of Generic Drugs (OGD) on the same business day are submitted at the
same time for 180-day exclusivity purposes," each receiving 180 days of exclusivity
without being subject to the other's exclusivity.50 In an accompanying petition, Zenith
Goldline sought a stay of approval of a competitor's ANDA until its own product
received approval. 5' In a February 2001 response to the citizen petition, FDA indicated
that it expected to conclude its evaluation shortly.'52 In July 2003, FDA issued a guid-
142 Id. at 79.
141 Id. at 80.
'" Id. at 81.
115 Purepac v. Thompson, 354 F.3d at 889.
146 TorPharm v. Thompson, 260 F. Supp. 2d at 82.
41 Id. at 75-76. A "section viii" statement states that the patent in question has been listed, but
does not claim a use for which the applicant seeks approval. 21 U.S.C. § 355(j)(2)(A)(viii). It does not
entitle the innovator to notice, and it does not entitle the ANDA applicant to exclusivity.
148 21 C.F.R. § 314.94(a)(12)(viii)(B).
149 Id. at 84; Purepac v. Thompson, 354 F.3d at 888.
150 Zenith Goldline Pharmaceuticals, Citizen Petition, 00P-1445/CPI (Aug. 8, 2000), available
at http://www.fda.gov/ohrms/dockets/dailys/00/AugOO/081100/cpOOOOl.pdf (last accessed May 17,
2004).
"I' Zenith Goldline Pharmaceuticals, Petition for Stay of Action, OOP-1443 (Aug. 8, 2000),
available at http://www.fda.gov/ohrms/dockets/dailys/00/AugO0/081000/psaOOOl .pdf (last accessed
May 17, 2004).
152 FDA, Letter to Zenith Goldline, OOP-1445/LET1 (Feb. 2, 2001), available at http://
www.fda.gov/ohrms/dockets/dailys/Ol/FebOl/021501letOOOl.pdf (last accessed May 17, 2004).
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ance document that provided for shared exclusivity in this situation,' and wrote the
petitioners separately to explain that the guidance "essentially" granted their citizen
petitions. 5 4
In the guidance document, FDA explained that when, on the same day, more than one
applicant submits an ANDA for the same drug containing a paragraph IV certification to
a listed patent, and no such certification was submitted previously, all such applicants
will share exclusivity.5 5 Exclusivity would be triggered for all of the first applicants for
a specific listed patent when one of them began to market its product (or on the date of
a court decision finding that patent invalid, unenforceable, or not infringed, if earlier).
The commercial marketing trigger would begin exclusivity as to all listed patents; a court
decision would trigger it only as to patents addressed in the decision.
3. TorPharm ("Shared Exclusivity")
On November 19, 2003, TorPharm sued FDA challenging its "shared exclusivity"
approach. 56 TorPharm was the first applicant to file an ANDA for a generic version of
Paxil® (paroxetine hydrochloride). TorPharm also was the first to submit a paragraph IV
certification challenging the only paroxetine patent listed at the time. On July 30, 2003,
FDA approved TorPharm's ANDA. On the same day, FDA determined that Alphapharm,
which had an ANDA pending, would be entitled to share exclusivity with TorPharm
because it was the first to file a paragraph IV certification to a later-listed paroxetine
patent. TorPharm launched its product on September 8, 2003-its 180-day exclusivity
would expire, therefore, on March 6, 2004. TorPharm filed suit, seeking a declaration that
FDA's shared exclusivity approach was unlawful and an order enjoining approval of
any other ANDA for paroxetine until March 6, 2004. The sole focus of the complaint was
FDA's decision to require TorPharm to share exclusivity with parties who were the first
to certify to a later-listed patent. (The agency's "multiple first applicant" shared exclu-
sivity policy was not at issue.) On January 2, the judge overturned FDA's decision.1 57
4. Purepac III ("Controlling Date")
On October 29, 2003, Purepac Pharmaceutical filed suit against FDA, challenging the
agency's view that when an ANDA applicant submits an amendment to certify to a
newly-listed patent, the controlling date for exclusivity purposes is the date it sent
notice to the patent-holder.'58
"I FDA, Guidance for Industry, 180-Day Exclusivity when Multiple ANDAs Are Submitted On
the Same Day (July 2003), available at http://www.fda.gov/cder/guidance/5710fnl.doc (last accessed
May 17, 2004).
1'5 FDA, Letter to IVAX Pharmaceuticals, OOP-1443/LET1 (July 31, 2003), available at http:I/
www.fda.gov/ohrms/dockets/dailys/03/AugO3/080403/00p-1443-letOOOl-ol-voll.pdf (last access May
17, 2004); FDA Letter to IVAX Pharmaceuticals, 00P-1445/LET2 (July 31, 2003), available at http://
www.fda.gov/ohrms/dockets/dailys/03/AugO3/080403/00p-1445-1etOO02-01-voll.pdf (last accessed
May 17, 2004). On May 13, 2003, Ranbaxy Laboratories submitted a citizen petition making the
same request as Zenith Goldline had made. Ranbaxy Laboratories, Citizen Petition, 03P-0217/CP1 (May
13, 2003), available at http://www.fda.gov/ohrms/dockets/dailys/O3/MayO3/052703/03P-0217-cpO001-
01-voll.pdf (last accessed May 17, 2004). FDA responded to this, too, on July 31. FDA Letter to Venable,
Baetjer, Howard & Civiletti, 03P-0217/LET1 (July 31, 2003), available at http://www.fda.gov/ohrms/
dockets/dailys/03/AugO3/080403/03p-0217-letOOOl-Ol-voll.pdf (last accessed May 17, 2004).
155 This was the approach FDA had proposed in 1999. See 64 Fed. Reg. 42,873 (Aug. 6, 1999).
The citizen petitions had asked the agency to maintain this approach despite withdrawal of the rule
(for unrelated reasons) in 2002. See Dockets OOP-1445 and 03P-0217.
156 TorPharm, Inc. v. FDA, No. 1:03CV02401 (D.D.C. filed Nov. 19, 2003).
15' TorPharm, Inc. v. FDA, 2004 WL 64064 (D.D.C. Jan. 8, 2004); see also Court Reverses FDA
Decision That Torpharm Shares Paxil 180-Day Award, FDA WEEK, Jan. 9, 2004, at 1.
"I' Purepac Pharm. Co. v. Thompson, No. 1:03CV02210 (D.D.C., filed Oct. 29, 2003).
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In July 2002, Purepac had filed an ANDA seeking to market a generic version of
Glucophage XR® (metformin hydrochloride extended release). On November 5, the U.S.
Patent and Trademark Office (PTO) issued another patent claiming metformin hydro-
chloride. FDA listed the patent in the Orange Book on November 21. On November 5,
and on every subsequent business day through November 25, Purepac submitted a
paragraph IV certification to that patent. On November 27, Purepac sent notice of the
paragraph IV certification to Bristol-Myers Squibb (BMS), the patent-holder. BMS re-
ceived that notice letter on December 3. IVAX filed its ANDA after Purepac amended its
ANDA, but before Purepac sent notice to BMS. IVAX included a paragraph IV certifica-
tion to the second patent, and notified BMS at that time. FDA awarded exclusivity to
IVAX and not to Purepac, reasoning that the controlling dates for determination of "first
applicant" status were Purepac's notice date (because Purepac was amending its ANDA)
and WAX's certification date (because IVAX was filing an original ANDA). 159 FDA
approved IVAX's product on October 28, and the company began shipping the product
that same day. Purepac immediately obtained a restraining order, and FDA suspended
its approval on October 30. The parties settled the lawsuit by agreeing to share profits
during the exclusivity period, and the judge dismissed the case on November 26.160
IV. HATCH-WAXMAN REFORM IN 2003
A. Reform Bills
Numerous bills to amend the Hatch-Waxman Amendments were introduced in the
106th and 107th Congresses. Many were drafted and introduced in response to the
generic industry's complaint that generic market entry was being delayed in a manner
not originally intended by Congress, by virtue of innovator practices as well as agency
and judicial interpretation of the statute. Some bills purported to be limited to implement-
ing the recommendations of the FTC in its 2002 report, others were considerably more
sweeping in their scope.
1. $812
An example of the latter was S 812, introduced by Senator Schumer (D-NY) and
Senator McCain (R-AZ) in May 2001. Among other things, bill 812 would have required
a patent owner to list its patent by a date certain or forever lose its right to sue an ANDA
holder for patent infringement. Also, if a patent holder failed to bring an infringement
action within forty-five days of receiving a paragraph IV notice, the patent holder would
be forever barred from bringing that suit. Like many of the other bills introduced in the
106th and 107th Congresses, S 812 also would have made changes to the 180-day
exclusivity provisions. For example, it would have effectively reinstated FDA's "suc-
cessful defense" requirement by requiring the ANDA holder to itself be sued for in-
fringement of the patent in question and by making loss of litigation a forfeiture event,
resulting in loss of exclusivity. 6' Although S 812 contained provisions addressing 180-
day exclusivity, these were not its primary feature. S 812 passed the Senate, on July 31,
159 Glucophage XR Settlement: Purepac, IVAX Split Generic Profits for 180 Days, F-D-C REP.
("The Pink Sheet"), Dec. 1, 2003, at 17.
"6 See IVAX, Purepac Settle Metformin 180-Day Generic Drug Exclusivity Suit, FDA WEEK, Dec.
5, 2003, at 15.
16 See section II.C.1, above.
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2002, by a vote of 78 to 21, but the House ignored the legislation entirely and the bill died
in the 107th Congress. 6
2
2.S 1225
On June 4, 2003, Senators Gregg (R-NH), Schumer (D-NY), McCain (R-AZ), and
Kennedy (D-MA) announced that they had reached agreement on proposed legislation
to amend the Hatch-Waxman Amendments. On June 10, 2003, Senator Gregg introduced
the legislation in question-S 1225, the "Greater Access to Affordable Pharmaceuticals
Act." The Senate Health, Education, Labor, and Pensions (HELP) Committee approved
the bill on June 11 by unanimous consent.
Although this bill dealt with many other aspects of the Hatch-Waxman Amendments,
one section specifically addressed 180-day exclusivity. In particular, the bill amended
the "court decision" trigger for generic exclusivity from a trial court decision to an
appellate decision (i.e., restoring the rule that had lasted from 1984 through 2000). It
established several circumstances under which the first generic applicant would forfeit
its 180-day exclusivity, including failure to market the drug within sixty days after the
ANDA was approved or a favorable appellate court decision, whichever was later. If
exclusivity was forfeited, it would not roll over to the next applicant.
S 1225 also provided that 180-day exclusivity would be available to the "first appli-
cant submitting an application for a drug with respect to any patent without regard to
whether an application has been submitted for the drug under this subsection contain-
ing such a certification with respect to a different patent." This was intended to limit
exclusivity to the first to challenge any patent claiming a drug, and to deny it to subse-
quent applicants who might challenge other patents claiming the same drug. Put an-
other way, exclusivity would be product-by-product rather than patent-by-patent. The
180-day provisions of S 1225 would apply only to applications filed under section 5050)
after the date of its enactment, and only with respect to listed drugs for which no
paragraph IV certification was made before the date of enactment. If, however, a generic
applicant forfeited exclusivity under the new section 505(j)(5)(D)(i)(VI) (due to an
anticompetitive agreement with the patent owner), the applicant would forfeit exclusiv-
ity "without regard to when" it made its paragraph IV certification.
3.S1
On June 19, 2003, the Senate adopted a narrowed version of the Gregg-Schumer bill
as an amendment (amendment 945) to the Medicare prescription drug legislation (S 1) by
a vote of 94 to 1.163 The version of the bill passed by the Senate differed in several
respects from the version marked up by the HELP Committee the prior week, including
with respect to 180-day exclusivity. Notably, the "court decision" trigger was deleted, in
favor of using only commercial marketing as the trigger. The provision for forfeiture for
failure to market was much more complex than in the earlier bill. Exclusivity would be
forfeited if the generic failed to market its drug within seventy-five days after at least one
of the following with respect to each patent challenged by the generic: an appellate
decision in the generic's favor; a settlement finding the patent invalid or not infringed;
62 The companion bill in the House, HR 1862, was referred on June 1 to the House Energy and
Commerce Committee's Subcommittee on Health. Neither the subcommittee nor the full committee
considered the legislation, however, and it was never considered on the House floor.
163 Senator Hatch cast the sole dissenting vote.
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patent expiry; or patent withdrawal. The new language added a provision for forfeiture
if all patents qualifying the first applicant for exclusivity had expired. Exclusivity was to
be shared among all first applicants who filed substantially complete applications on the
same day, rather than belonging to the applicant who filed earliest on that day. Approval
of subsequent ANDAs was to be permitted if all first applicants forfeited exclusivity;
there was no rolling exclusivity."6
4. HR1
Throughout most of June 2003, House leadership and the House Energy and Com-
merce Committee (the committee ofjurisdiction) worked to prepare a scaled-back House
alternative to S 1225. Following the Energy and Commerce Committee's markup of the
House Medicare bill (HR 1), the alternative language was perfected with input from
relevant stakeholders and FDA. On June 26, the House Rules Committee met to consider
HR 1 (the House Medicare bill that would meet up with S 1 in the ensuing conference)
and reported out a rule for consideration of the bill on the floor. During Rules Committee
consideration, an amendment in the nature of substitute was offered and adopted. The
House alternative provisions to reform the Hatch-Waxman Amendments were included
in Title XI of the adopted Rules Committee substitute. While other parts of the House
alternative contained significant differences, the 180-day exclusivity language was iden-
tical to that in S 1.
On June 26, the House approved HR 1 by a vote of 216 to 215, and the Senate
approved S 1 by a vote of 76 to 21.165 Thus began the historic House-Senate conference
committee to fashion the final language of the Medicare reform legislation.
B. Conference
While the Medicare bills were in conference, a concern was raised about the interplay
of several of the provisions relating to 180-day exclusivity. As noted above, exclusivity
would begin only upon commercial marketing. Exclusivity would be forfeited if the ge-
neric failed to market its drug within seventy-five days after at least one of the following
with respect to each patent challenged by the generic: an appellate decision in the
generic's favor; a settlement finding the patent invalid or not infringed; patent expiry; or
patent withdrawal. The result, however, was that a generic had an incentive to file an
164 In another amendment (amendment 974) to S 1, the Senate approved language requiring
generic drug applicants and brand name companies to notify the Department of Justice and the FTC
of any agreement regarding 180-day exclusivity and that applicant's ANDA or any other ANDA
based on the same innovator drug. Senate Amendment 974 to S 1, available at http://thomas.loc.gov/
cgi-bin/bdquery/z?d108:SP00974 (last accessed May 17, 2004).
165 On June 17, 2003, the Senate Judiciary Committee held a hearing on the FTC Report, the
report's relationship to FDA's new Hatch-Waxman regulations (68 Fed. Reg. 36,676 (June 18,
2003)), and S 1225. The FTC Study on Barriers to Entry in the Pharmaceutical Marketplace: Hearing
Before the Senate Judiciary Comm., 108th Cong. 1st Sess (2003), available at http://
judiciary.senate.gov/hearing.cfm?id=812 (last accessed May 17, 2004). The first panel consisted of
the Chair of the FTC, the Chief Counsel of FDA, and a representative of the Department of Justice.
Representatives of PhRMA, the Generic Pharmaceutical Association (GPhA), and the Consumer
Federation of America spoke on the second panel. Several of the witnesses addressed 180-day
exclusivity. The prepared statement of the FTC, for example, restated the findings of its 2002 report.
Testimony of the Honorable Timothy J. Muris, Chairman, Federal Trade Commission (June 17,
2003), available at http://judiciary.senate.gov/testimony.cfm?id=812&wit-id=2251 (last accessed
May 17, 2004).
Senate Judiciary Committee Chairman Hatch (R-UT) expressed concern that the 180-day
provision would encourage more, and earlier, challenges of dubious merit.
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early challenge to both the basic drug substance patent and the drug formulation pat-
ents. If the generic won on all of the patents, it could-indeed, must-market the drug
early. If the generic lost on the basic patent-which usually is the case-, and won on
any of the others, it could wait until expiration of the basic patent to market the drug,
which could be another eight or ten years. This is because the failure to market provi-
sion would not kick in until the last challenged patent had expired. No forfeiture would
occur until seventy-five days after the basic patent expired. Arguments were made that
this would encourage generic manufacturers to file speculative patent challenges very
early in the process to market the drug. In short, the argument continued, the new
legislation would transform early and speculative patent challenges from an intention-
ally high-risk uncertain-reward gambit to a virtually no-risk and guaranteed-reward propo-
sition, effectively enabling the generic industry to adopt patent challenges as its busi-
ness model."6
The conference committee issued its report on November 20.167 Under the new lan-
guage, if an ANDA contains a paragraph IV certification and "is for a drug for which a
first applicant has submitted an application containing such a certification" (i.e., is for a
drug for which someone else submitted an ANDA earning it exclusivity), the application
"shall be made effective on the date that is 180 days after the date of the first commercial
marketing of the drug (including the commercial marketing of the listed drug) by any first
applicant."' 65 The term "180-day exclusivity period" means "the 180-day period ending
on the day before the date on which an application submitted by an applicant other than
a first applicant could become effective under this clause."' 69 The term "first applicant"
means "an applicant that, on the first day on which a substantially complete application
containing a [paragraph IV] certification is submitted for approval of a drug, submits a
substantially complete application that contains and lawfully maintains a [paragraph IV
certification]. 7"'7 A "substantially complete application" is "an application under this
subsection that on its face is sufficiently complete to permit a substantive review and
contains all the information required" under section 505(j)(2)(A) of the FDCA. 7
The first applicant forfeits exclusivity if it fails to market the drug by the later of(a) the
earlier of 75 days after approval of the application of the first applicant is made effective
under section 505(j)(5)(B)(iii), or 30 months after submission of the application of the first
applicant; or (b) with respect to the first applicant or any other applicant (that has received
tentative approval), 75 days after the date as of which, as to each of the patents with
respect to which the first applicant submitted and lawfully maintained a paragraph IV
certification qualifying it for exclusivity, at least one of the following has occurred:
166 For a discussion of this issue, see Eli Lilly, Hatch 180-Day Award Concerns May Slow Hatch-
Waxman Deal (Aug. 7, 2003), at www.InsideHealthPolicy.com; CBO Says Generic Rx Language in
Both Medicare Bills Could Delay Drug Competition, HEALTH CARE DAILY, Sept. 2, 2003. On August 1,
the Senate Judiciary Committee held a second hearing, at which representatives of the FTC, DOJ,
FDA, and PTO testified, as did a representative of Eli Lilly. Examining the Senate and House Versions
of the "Greater Access to Affordable Pharmaceuticals Act: Hearing Before the Senate Judiciary
Comm., 108th Cong. 1st Sess. (2003), available at http://judiciary.senate.gov/hearing.cfm?id=891
(last accessed May 17, 2004). The Eli Lilly representative explained this concern about "parking" of
180-day exclusivity. Robert A. Armitage, Testimony on Behalf of Eli Lilly and Company Before the
Committee on the Judiciary, United States Senate, on the "Greater Access to Affordable Pharmaceu-
ticals Act" (Aug. 1, 2003), available at http://judiciary.senate.gov/testimony.cfm?id=891&witid=2496
(last accessed May 17, 2004).
167 H. REP. No. 108-391 (Nov. 20, 2003).
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(1) in an infringement action brought against that applicant with respect to the patent,
or in a declaratory judgment action brought by that applicant with respect to the
patent, a court enters a final decision from which no appeal (other than a petition to
the Supreme Court for a writ of certiorari) has been or can be taken that the patent
is invalid or not infringed;
(2) in an infringement action or a declaratory judgment action, a court signs a settle-
ment order or consent decree that enters a final judgment that includes a finding
that the patent is invalid or not infringed; or
(3) the patent information submitted under section 505(b) or (c) is withdrawn by the
holder of the application approved under section 505(b). 7 2
Most of the changes in the conference report were minor. In the only real substantive
changes, the conferees addressed the concern about interplay of the new forfeiture and
trigger provisions. First, the conferees deleted the provision requiring forfeiture 75 days
after every challenged patent expires. Second, to qualify as a "first applicant," a generic
manufacturer would be required to "lawfully maintain" a paragraph IV certification.
Third, the failure-to-market forfeiture event applies only to patents for which a para-
graph IV certification had been lawfully maintained. Thus, if an ANDA applicant loses
a patent challenge (for example, to a basic patent), that patent challenge no longer
qualifies the applicant for exclusivity. The 75-day forfeiture clock begins to run as soon
as it prevails on a different patent. Put another way, if a generic company challenges a
formulation patent but adds a frivolous challenge to the basic patent, prevails on the
formulation patent and loses on the basic patent, then the 75-day clock begins to run.
This precludes "parking" exclusivity by challenging two patents, knowing one will lose
on the patent that is not due to expire for some time. Now the generic applicant forfeits
exclusivity if it cannot market within 75 days of the appellate decision on a patent it
successfully challenged.173
The following scenario also would result in forfeiture.
Step 1. The first applicant withdraws the application or the Secretary considers the
application to have been withdrawn as a result of a determination by the Secretary that
the application does not meet the requirements for approval.
Step 2. The first applicant amends or withdraws the certification for all of the patents
with respect to which that applicant submitted a certification qualifying the applicant for
the 180-day exclusivity period.
Step 3. The first applicant fails to obtain tentative approval of the application within
30 months after the date on which the application is filed, unless the failure is caused by
a change in, or a review of, the requirements for approval of the application imposed
after the date on which the application is filed.
Step 4. The first applicant enters into an agreement with another applicant under this
subsection for the drug, the holder of the application for the listed drug, or an owner of the
patent that is the subject of the paragraph IV certification, the FTC or the Attorney General
files a complaint, and there is a final decision of the FTC or the court with regard to the
complaint from which no appeal (other than a petition to the Supreme Court for a writ of
certiorari) has been or can be taken that the agreement has violated the antitrust laws.
Step 5. All of the patents as to which the applicant submitted a certification qualify-
ing it for the 180-day exclusivity period have expired. If all first applicants forfeited the
180-day exclusivity period, no applicant would be eligible for a 180-day exclusivity
period. In other words, there would be no rolling exclusivity.
"I Id. at 401.
173 In a sense, in the new language forfeiture substitutes for the court decision trigger.
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C. Passage
On November 22, the House approved the conference report by a vote of 220 to 215,
and on November 25, the Senate approved the conference report by a vote of 54 to 44.
There was no discussion of the bill's intellectual property provisions on the House
floor. There was very little discussion on the Senate floor, and even less of the 180-day
exclusivity portion. 17 4 Senator Schumer, for example, briefly discussed the new forfei-
ture provisions as a means of ensuring that exclusivity "cannot be used as a bottle-
neck," and Senator Frist noted that the bill took "steps to reduce or eliminate the delays
in the movement of generic drugs to the marketplace."' 75 The formal legislative history
of the new language is sparse. The conference report contains no discussion of the new
180-day exclusivity provision in the bill reported out of the conference committee. Presi-
dent Bush signed the new Act into law on December 8.
V. CONCLUSION
The new law of 180-day exclusivity is quite different from the old. Chief among the
differences are deletion of the court decision trigger, which had prompted so much
litigation, and inclusion of forfeiture provisions to force generic manufacturers to mar-
ket promptly. The conferees mooted or resolved a number of the issues that had arisen
between 1984 and 2003, including whether there would be shared and multiple exclusiv-
ity, whether there could be rolling exclusivity, and what level court decision is required
to trigger exclusivity. Some of these issues will remain, however, for "old" ANDAs.1
76
There will be new interpretive questions arising under both the new and the old lan-
guage. A citizen petition filed on February 17, 2004, by Mylan Pharmaceuticals has
raised one such issue. 71 Mylan argues that so-called "authorized generics" (private
label versions of the innovator product that are manufactured and supplied by the
innovator) are "generic" drugs and therefore subject to (not permitted to market during)
the exclusivity period awarded to the first generic applicant. The company also argues
that the "emerging trend" of marketing authorized generics "will negatively affect the
incentive given to generic manufactures to challenge drug patents."'7 8
The new scheme undoubtedly also will give rise to new interpretive questions. On
December 9, 2003, Senate Judiciary Committee Chairman Hatch raised one such issue on
the Senate floor. When the first-to-file has not yet marketed its product, and exclusivity
has neither begun to run (the applicant has not gone to market) nor been forfeit (75 days
have not elapsed since approval), and a second-to-file prevails in a challenge to the
validity of the underlying patent, what result obtains?
Senator Hatch reported having been told by conferee staff that the successful chal-
lenge would cause forfeiture of the first-to-file's exclusivity. Senator Hatch argued,
17 For the limited discussion of the Hatch-Waxman provisions, see 149 CONG. REc. S15567
(statement of Sen. Hatch), id. at S15688 (statement of Sen. McCain), id. at S15690 (statement of
Sen. Hatch), id. at S15745-46 (statement of Sen. Schumer), id. at S15751-52 (statement of Sen.
Kennedy), id. at S15760-61 (statement of Sen. Frist (R-TN)); and id. at S15884-86 (statements of
Sens. Kennedy, Schumer, and McCain).
1 149 CONG. REc. S15746 (statement of Sen. Schumer); id. at S15761 (statement of Sen. Frist).
176 The sole exception, discussed supra at section II.D., is the issue of the "court decision"
trigger, which Congress resolved retroactively.
177 Mylan Pharmaceuticals, Inc., Citizen Petition, 2004P-0075/CP1 (Feb. 17, 2004), available
at http://www.fda.gov/ohrms/dockets/dailys/04/febO 4/02 1 804/04p-0075-cpOOOOl-voll.pdf (last ac-
cessed May 17, 2004).
178 Id. at 2.
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however, that the successful challenge could effectively penalize the successful subse-
quent challenger. This would result as follows: ordinarily, the first applicant would have
75 days to come to market, after approval. If a second applicant prevailed in a patent
challenge, however, forfeiture would not occur until the later of. 1) 75 days after the first
applicant's approval, or 2) 75 days after the second applicant's successful appellate
decision. The first applicant could wait, therefore, until day 74 after that second
applicant's victory, and then launch its product, thereby enjoying the 180 days of
exclusivity. Senator Hatch argued that this would not be a sensible outcome, and sug-
gested that in this case, it would even be preferable if the exclusivity were granted to the
second-to-file. This, of course, would require a statutory amendment. 79
Further, the general policy in favor of maintaining 180-day exclusivity may continue
to be questioned. A serious question remains, for example, whether the exclusivity
incentive is even necessary in 2004, because there is ample evidence that generic manu-
facturers will file ANDAs even when they have no hope of exclusivity.8 0
Another question is whether the incentive of 180-day exclusivity should be limited to
generic manufacturers who prove the innovator's patent is invalid, rather than also be
given to generic manufacturers who simply design around the innovator's patent, clear-
ing the way to market only for themselves. On December 9, 2003, the day after President
Bush signed the Medicare conference report into law, Hatch raised this issue on the
Senate floor, pointing out the "incongruity" of "awarding 180 days both for a successful
invalidity challenge and a noninfringement action." The latter, he noted, benefits only a
specific party, the noninfringing generic manufacturer, rather than clearing the way for
generic market entry in general.' There may be good policy reasons to revisit the
continued availability of exclusivity in this situation, and Senator Hatch may be well
poised to introduce the necessary legislative amendments, but with several years' worth
of efforts to "reform" Hatch-Waxman finally off the table, policymakers may find they
want several years to take stock of the new law, before returning to the drafting table.
'7 149 CONG. REC. S16104 (daily ed. Dec. 9, 2003) (remarks of Sen. Hatch).
ISO In the case of Prilosec ®, for example, eight generic manufacturers filed ANDAs containing
paragraph IV certifications of noninfringement even while Andrx's exclusivity had not yet begun to
run.
181 149 CONG. REc. S16104 (daily ed. Dec. 9, 2003) (remarks of Sen. Hatch).
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